Reduced estimated glomerular filtration rate (eGFR <60 mL/min/1.73 m 2 ) at first transurethral resection of bladder tumour is a significant predictor of subsequent recurrence and progression 
Introduction
Moderate chronic kidney disease (CKD) is defined as an eGFR of <60 mL/min/1.73 m 2 [1] . Many patients with urothelial carcinoma will present with CKD. The prognostic value of eGFR is not commonly evaluated as a clinical variable to predict patient outcomes. Most patients with nonmuscle-invasive bladder cancer (NMIBC) will harbour lowrisk tumours (low grade stage Ta) and be spared the risk of disease progression [2] . Yet, low-risk NMIBC has high recurrence rates exposing individuals to multiple repeat cystoscopies and intravesical therapy [3] . Higher-risk NMIBC, carcinoma in situ (CIS) or high-grade Ta/T1 lesions have the potential for stage progression [4, 5] . Progression to muscleinvasive urothelial carcinoma requires more aggressive surgical management with radical cystectomy and the possibility of reduced survival rates [6] . It is therefore important to consider all patient characteristics that may impact tumour recurrence and progression in NMIBC. CKD may contribute to reduced survival rates and can be considered as a potential important variable to evaluate when estimating patient outcomes. Furthermore, knowledge of renal function may alter management of NMIBC, if individual risk of cancer progression is established.
Moderate CKD (eGFR <60 mL/min/1.73 m 2 ) may be a predictor of NMIBC survival outcomes with respect to tumour recurrence and progression [7] . Although limited by small patient numbers, the study by Rausch et al. [7] demonstrated CKD as an independent predictor of tumour recurrence and progression to muscle invasion. Currently, explanations for an association between CKD and poorer outcomes in NMIBC have not been established. Hypotheses concerning CKD and urothelial tumour growth and proliferation do exist and include elevated levels of inflammatory markers in urine of those with CKD [8] , as well as the related immunological dysfunction inherent to renal functional decline [9] . There are many well-established variables that have been identified as predictors of worse outcomes in patients with NMIBC. While little is known about the association between CKD and reduced NMIBC survival outcomes, management of non-invasive urothelial carcinoma may be altered in those harbouring CKD. The objective of the present study was to determine if moderate CKD (eGFR <60 mL/min/1.73 m 2 ) was a significant predictor of tumour recurrence and progression in patients with NMIBC after transurethral resection of bladder tumour (TURBT).
Patients and Methods
After Institutional Review Board approval, data on patients with NMIBC were collected from 2000 to 2014. Patient data were derived from two separate institutional databases (University of Wisconsin, WI and University of Rochester, NY, USA). Only patients with NMIBC after their first TURBT were studied. Available data for patients who had a repeat TURBT were reviewed and any patient who had muscle invasion after a second procedure was excluded. Patients who had concomitant upper tract urothelial carcinoma were excluded. Data available were collected to calculate an estimated GFR according to the CKDepidemiology collaboration formula [10] .
Tumour recurrence was defined as evidence of tumour after a subsequent TURBT and was confirmed after pathological review. Progression was defined as evidence of muscle invasion on subsequent TURBT (T2 stage progression) or any increase in grade or stage i.e. Ta to T1 or CIS (any progression). Independent variables assessed included age, gender, diabetes, smoking history, tumour multifocality, tumour grade, tumour stage, intravesical chemotherapy, bacille calmette guerin (BCG) therapy, tumour size, and eGFR.
Univariate and multivariable Cox proportional hazard regression models with backwards selection were used to analyse associations between variables and tumour recurrence and progression. Recurrence-free survival (RFS) and progression-free survival (PFS) curves were generated using the Kaplan-Meier method and compared using the log-rank test. Variables with a P < 0.05 were considered statistically significant. Statistical analysis was done using the Statistical Analysis System (SAS) version 9.2 (SAS Institute, Cary, NC, USA).
After multivariable analysis to identify predictors of recurrence and progression, prediction models were developed for RFS and PFS rates. According to significant variables from our multivariable analysis, a numerical point value was assigned for each risk factor present in patient histories. A value of 0, 1, or 2 was given representing risk factors and Kaplan-Meier estimates were developed to demonstrate survival based on the number of risk factors present.
Results
In all, 727 patients, from 2000 to 2014, were identified from the two institutional databases and were included in the study. Data were available for 632 patients with eGFR for analysis. Clinical and pathological characteristics for the entire population are shown in Table 1 , whilst those of the 632 patients with eGFR data are shown in At the last follow-up, 400 (55%) patients had tumour recurrence, whilst 145 (19.9%) had tumour progression and 41 (5.6%) patients went on to progress to muscle-invasive disease. Univariate and multivariable Cox proportional regression hazards were performed to determine characteristics associated with disease recurrence and progression and are outlined in Table 3 . On univariate analysis, variables associated with tumour recurrence included multifocal tumours (P = 0.02), tumour size >3 cm (P = 0.003), and an eGFR of <60 mL/min/1.73 m 2 (P < 0.001). Multivariable analysis identified tumour size >3 cm (hazard ratio [HR] 1.4, 95% CI: 1.1-1.8; P = 0.01) and an eGFR of <60 mL/min/1.73 m 2 (HR 1.5, 95% CI: 1.2-1.9; P = 0.002) as predictors of tumour recurrence.
Tumour progression was defined as any progression (noninvasive upstaging or increase in grade) and T2 progression. Univariate analysis identified age (P = 0.05), tumour multifocality (P = 0.03), stage T1 (P = 0.001), high grade (P < 0.001), and an eGFR of <60 mL/min/1.73 m 2 (P < 0.001), as being associated with progression to T2 muscle-invasive disease. After multivariable analysis, high-grade tumours (HR 4.6, 95% CI: 1.7-12; P = 0.002) and an eGFR of <60 mL/min/1.73 m 2 (HR 3.7, 95% CI: 1.8-7.9; P = 0.001) were identified as independent predictors of tumour progression to muscle-invasive disease. An eGFR of <60 mL/min/1.73 m 2 was also an independent predictor of any progression (HR 1.7, 95% CI: 1.1-2.5; P = 0.01).
The eGFR was then analysed as a continuous variable and indeed it remained significant for predicting survival outcomes with regard to recurrence (HR 0.92, 95% CI: 0.88-0.96; P < 0.001), T2 progression (HR 0.75, 95% CI: 0.63-0.88; P < 0.001), and any progression (HR 0.86, 95% CI: 0.79-0.94; P < 0.001). As eGFR increased, we recognised improved survival outcomes, as individuals were less likely to experience recurrence or progression among our population of patients with NMIBC. Lastly, we sought to determine the impact of CKD on NMIBC in those who underwent BCG therapy. We performed subgroup analysis comparing all patients who underwent BCG therapy stratifying them by an eGFR >60 and <60 mL/min/ 1.73 m 2 (Table S1 ). Tumour recurrence and progression were assessed and after multivariable analysis for T2 progression, those who received BCG therapy and who had CKD were more likely to experience tumour progression to muscle-invasive disease (HR 7.2, 95% CI: 1.93-26.50; P = 0.003) compared to patients who received BCG and did not have CKD.
Survival rates were determined according to the Kaplan-Meier method. Kaplan-Meier estimates for RFS and PFS rates are shown in Fig. 1A ,B. The 5-year RFS rate for an eGFR of >60 mL/min/1.73 m 2 was 46%, whilst it was just 27% for an eGFR of <60 mL/min/1.73 m 2 (P < 0.001). The 5-year PFS rates were 83% for an eGFR of >60 mL/min/1.73 m 2 and 71% for an eGFR of <60 mL/min/1.73 m 2 (P = 0.01). From the survival analysis, prediction models were developed for recurrence and progression ( Fig. 2A,B) . Risk factors from the multivariable analysis for tumour recurrence included tumour size >3 cm and an eGFR of <60 mL/min/1.73 m 2 , and for progression included high-grade tumours and an eGFR of <60 mL/min/1.73 m 2 . The 5-year RFS rates for patients with 0, 1, and 2 risk factors were 54%, 36%, and 28% (P = 0.001), respectively. The 5-year PFS rates for patients with 0, 1, and 2 risk factors were 98%, 96%, and 84% (P < 0.001), respectively. 
Discussion
In the present study, we assessed the impact of CKD (eGFR <60 mL/min/1.73 m 2 ) on the risk of NMIBC recurrence and progression. Those who had CKD at the time of their first TURBT were more likely to have tumour recurrence. Our present analysis revealed that tumour size >3 cm and an eGFR of <60 mL/min/1.73 m 2 were predictors of disease recurrence. When cancer progression was assessed, an eGFR of <60 mL/min/1.73 m 2 was predictive of superficial progression (any increase in T Stage, Ta to T1, or grade) as proposed by Lamm et al. [11] . Likewise, CKD was also associated with tumour progression to muscle-invasive disease or stage T2. High-grade tumours and an eGFR of <60 mL/min/1.73 m 2 were independent predictors of muscle-invasive disease. We also found that those with CKD who were treated with BCG for NMIBC were more likely to progress to muscle invasion than those who did not have evidence of renal dysfunction. From these results, we developed prediction models based on an eGFR of <60 mL/min/1.73 m 2 outlining patient characteristics that may predict worsening survival outcomes in NMIBC.
The association between CKD and worse survival outcomes for NMIBC remains poorly understood. Previous studies have identified a link between CKD and the risk of developing cancer [12] [13] [14] . Moreover, much less is known about the association between moderate CKD and cancer risk. In a retrospective analysis of 3 654 senior individuals with a median 10 years of follow-up, Wong et al. [15] showed that men had an increased risk of developing cancer beginning at an eGFR of 55 mL/min/1.73 m 2 . They further demonstrated the risk of urinary tract tumours to be increased in men with CKD. More recently, in a retrospective population-based cohort of over a million people from 2000 to 2008, the authors reported that compared to an eGFR of 60-89 mL/min/1.73 m 2 , those with an eGFR of <30 mL/min/1.73 m 2 had a 48% increased risk of developing urothelial carcinoma [16] . Rausch et al. [7] found that an eGFR of <60 mL/min/1.73 m 2 predicted tumour recurrence and progression. The authors were then able to develop a risk prediction model for recurrence.
Mechanisms underlying the relationship between CKD and cancer are not well recognised. However, alterations in immune function seem to be well established in light of CKD and the result appears to be global dysfunction effecting both adaptive and innate immune systems [17] . In CKD, the innate immune system demonstrates increased pro-inflammatory cytokines and hyporeactive white blood cells [18, 19] , whilst adaptive immunity shows impaired T-cell activation/function and altered antigen presentation [20, 21] . A paramount feature of NMIBC progression may be related to T-cell downregulation, as many high-risk patients receive BCG therapy, a treatment predicated on generating a helper T-cell response [22] . Although merely speculative, a relationship between high-risk NMIBC progression and adaptive immune dysfunction is highlighted by our present finding that patients with an eGFR of <60 mL/min/ 1.73 m 2 were more likely to progress to muscle-invasion compared to those with an eGFR of >60 mL/min/1.73 m 2 receiving BCG therapy. This supports considering a change in bladder cancer management on an individual patient basis for continued intravesical immunotherapy vs radical cystectomy, as CKD may be associated with BCG failure.
Likewise, another possible explanation for decreased survival outcomes for patients with NMIBC with evidence of CKD is the alteration of urine constituents. Patients with CKD often have albuminuria on urine analysis [23] . With a decade of follow-up involving >5 000 patients, Jørgensen et al. [24] confirmed that those with the highest levels of albuminuria had the greatest cancer risk and an eight-fold increased risk of developing bladder cancer. These findings, combined with increased urinary cytokines and inflammatory markers in those with CKD [25] , may account for further cell turnover and eventual neoplastic conversion. In the present multi-institutional study, we confirm that CKD or an eGFR of <60 mL/min/1.73 m 2 is associated with reduced RFS and PFS. From our multivariable analysis, we were able to develop prediction models incorporating eGFR with other tumour characteristics to identify those at greatest risk of experiencing recurrence and progression. In both models, an eGFR of <60 mL/min/1.73 m 2 was consistently predictive of decreased RFS and PFS rates. The ability to identify patients likely to progress and fail intravesical therapies has significant implications for managing patients with bladder cancer with renal dysfunction. Our present findings are further supported after eGFR was associated with worsening outcomes when analysed as a continuous variable and stratified by different stages of CKD. If eGFR is truly a predictor of decreased RFS and PFS, it may indeed be important to include it in existing prognostic scoring systems to evaluate patients for more aggressive management and surveillance given the increased rate of intravesical therapy failure. Notwithstanding, our present findings require future validation with population-based longitudinal studies to determine if eGFR can be incorporated into prediction models to assess disease course.
Our present study has several limitations including its retrospective nature with possible selection bias. Furthermore, following eGFR out longitudinally would provide a more accurate representation of our population's overall renal function. Additionally, many factors associated with worse renal function, including medications to treat it or the coexisting conditions that may have contributed to renal dysfunction, were not recorded and may have contributed to urothelial carcinoma development, recurrence or progression. Our present data also represents data from tertiary referral centres and may not reflect that seen in the general population. The multi-institutional nature of our present study created a heterogeneous population and may contribute to certain confounding factors inherent to a retrospective review analysis. However, combining datasets from two distinct geographical centres increases the validity of our present findings and argue for further hypothesis generating analysis. As a continuous variable, eGFR proved a predictor of tumour recurrence and progression. Finally, we also showed that with worsening stages of CKD, eGFR was associated with increased likelihood of poorer outcomes. Validation with population-based studies with larger patient 
Conclusions
Assessing eGFR at the time of first TURBT, we show that CKD is a significant predictor of decreased RFS and PFS in patients with NMIBC. Findings reflect poorer outcomes for tumour recurrence and progression (T2, stage, or grade progression) for those with NMIBC and an eGFR of <60 mL/min/1.73 m 2 . This finding highlights a possible clinical application for eGFR when considering treatment for NMIBC. Larger populationbased studies are required to determine its clinical applicability. Patients with reduced renal function should be considered for increased surveillance after bladder cancer diagnosis.
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